Citation

Kayahan B, Veznedaroǧlu B. Klin. Psikofarmakol. Bül. 2006; 16(1): 52-62.

Copyright

(Copyright © 2006, Kadıköy Hachette Yayıncılık)

DOI

unavailable

PMID

unavailable

Abstract

The importance of depression in schizophrenia is much more emphasized in DSM-IV than DSM-III-R. Although in recent studies the three dimensional model (psychotic, disorganized, negative) is promoted in explaining symptoms of schizophrenia, there are some researchers who propose depression to be a distinct dimension in schizophrenia. The depressive symptoms in schizophrenia are frequent and commonly serious, and negatively influence the prognosis and recovery of the patient. The patients with comorbid diagnosis of schizophrenia an depression present a distinct mortality and morbidity profile including high recurrence and suicide risk. There are a few studies in the literature concerning the treatment of depressive symptoms in spite of their high frequency, prognostic significance and influence on psychosocial outcomes in schizophrenia. In this review, the importance of depressive symptoms in schizophrenia, the role and efficacy of antidepressants in the treatment of depressive symptoms and the effect of atypical antipsychotics with serotonin-dopamine antagonistic activity currently used in Turkey (clozapine, risperidone, olanzapine, quetiapine and ziprasidone) on depressive symptoms in schizophrenia are comprehensively discussed.

Language: tr

Keywords

human; Depression; suicide; prognosis; Schizophrenia; depression; schizophrenia; mortality; Antidepressants; comorbidity; clozapine; Pharmacotherapy; morbidity; review; symptomatology; antidepressant agent; disease association; quetiapine; recurrent disease; olanzapine; risperidone; atypical antipsychotic agent; ziprasidone; Turkey (republic); Atypical antipsychotics